Generation BioGBIO
GBIO
About: Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Employees: 115
0
Funds holding %
of 7,433 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
9.73% less ownership
Funds ownership: 71.19% [Q1] → 61.46% (-9.73%) [Q2]
26% less funds holding
Funds holding: 81 [Q1] → 60 (-21) [Q2]
32% less capital invested
Capital invested by funds: $19.3M [Q1] → $13.2M (-$6.11M) [Q2]
59% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 34
60% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 25
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
14%
upside
Avg. target
$10.67
74%
upside
High target
$15
145%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Canaccord Genuity Whitney Ijem | 63%upside $10 | Buy Maintained | 18 Aug 2025 |
Needham Gil Blum | 145%upside $15 | Buy Reiterated | 13 Aug 2025 |
Wedbush David Nierengarten | 14%upside $7 | Neutral Downgraded | 13 Aug 2025 |
Financial journalist opinion
Negative
Zacks Investment Research
2 weeks ago
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
Generation Bio Co. (GBIO) came out with a quarterly loss of $3.12 per share versus the Zacks Consensus Estimate of a loss of $2.8. This compares to a loss of $3.1 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results
• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of LAT1 and VAV1, targets potentially relevant to T cell-driven autoimmune diseases • Company is evaluating strategic alternatives to maximize value of its delivery system and potential therapeutics for T cell-driven autoimmune diseases for shareholders • Cash balance of $141.4M as of June 30, 2025 • Recent litigation settlement extinguishes lease liability CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced new data demonstrating that its cell-targeted lipid nanoparticle (ctLNP) system selectively delivered siRNA to T cells in non-human primates, reinforcing the company's belief that its ctLNP has the ability to deliver diverse genetic medicine payloads to multiple new cell types.
Neutral
GlobeNewsWire
1 month ago
Generation Bio Announces 1-for-10 Reverse Stock Split
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that it will implement a 1-for-10 reverse stock split of the issued shares of the Company's common stock (“Reverse Stock Split”), effective at 5:00 pm Eastern Time on July 21, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on June 4, 2025, with the final ratio subsequently determined by the Company's Board of Directors. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.
Neutral
GlobeNewsWire
1 month ago
Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that, on July 1, 2025, the company granted equity awards to one new employee, pursuant to the company's 2025 Inducement Stock Incentive Plan, as an inducement material to such new employee's entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
2 months ago
Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D.
Negative
Zacks Investment Research
3 months ago
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $1.12 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results
- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA - Lead target and portfolio strategy to be announced mid-2025 - Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, reported business highlights and first quarter 2025 financial results.
Neutral
GlobeNewsWire
4 months ago
Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th at 12:45 p.m. ET.
Negative
Zacks Investment Research
5 months ago
Generation Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue Estimates
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.53 per share a year ago.
Neutral
GlobeNewsWire
5 months ago
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases
Charts implemented using Lightweight Charts™